Aptose Biosciences Inc. logo
Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology
March 07, 2018 07:00 ET | Aptose Biosciences, Inc.
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose to Participate in Upcoming Investor Conferences In March 2018
March 06, 2018 07:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 06, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Inc. logo
Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus
February 07, 2018 16:01 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Inc. logo
FDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid Leukemia
December 26, 2017 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
Aptose Biosciences Inc. logo
Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting
December 11, 2017 16:04 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data from research led by The University of...
Aptose Biosciences Inc. logo
OHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual Meeting
December 11, 2017 16:04 ET | Aptose Biosciences, Inc.
PORTLAND, Ore. and SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- The OHSU Knight Cancer Institute and Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical...
Aptose Biosciences Inc. logo
Aptose Reports Results for the Third Quarter Ended September 30, 2017
November 14, 2017 16:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Inc. logo
Aptose To Release Third Quarter Ended September 30, 2017 Financial Results and Hold Conference Call on November 14, 2017
November 07, 2017 08:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Biosciences Inc. logo
Aptose to Present New CG’806 Data at the 2017 ASH Annual Meeting
November 01, 2017 11:14 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO), (TSX:APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Inc. logo
Aptose Enters into $15.5 Million Common Shares Purchase Agreement with Aspire Capital Fund, LLC
October 30, 2017 08:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated...